DGAP-News: Cannovum AG / Key word(s): Personnel Cannovum AG expands Supervisory Board and Medical Advisory Board 2021-09-08 / 13:44 The issuer is solely responsible for the content of this announcement.

-----------------------------------------------------------------------------------------------------------------------

Cannovum AG (stock exchanges Düsseldorf, Munich, Hamburg, Berlin, gettex: ISIN DE000A2LQU21) has appointed Priv. Doz. Dr. med. habil. Philipp Sewerin to the supervisory board. Dr. Sewerin is a specialist in internal medicine and rheumatology at the university clinic in Düsseldorf. In addition to his clinical activities, he's engaged in research and clinical trials, particularly on inflammatory rheumatic diseases. Dr. Sewerin is dedicated to the well-being of patients and is very involved in association work.

In addition to his position on the Supervisory Board, Dr. Sewerin will support Cannovum in an advisory capacity as a scientific expert and new member of the Medical Advisory Board. The field of internal medicine is a major application area of cannabis-based therapies. In addition to the well-known use of cannabis-based medicines in pain therapy, there is great potential for medical cannabis in the treatment of inflammatory diseases such as rheumatism. Dr. Sewerin will contribute his in-depth knowledge to Cannovum's Medical Education. This is an advanced training program to support healthcare professionals in setting up cannabis-based therapies.

"We are pleased to welcome Dr. Sewerin to the Board of Directors and Medical Advisory Board. His professional expertise in the field of internal medicine is an asset to Cannovum's Medical Education and he will support us in improving the care of medical cannabis patients," says Pia Marten, CEO of Cannovum AG.

Contact:

Linda Rasch, IR & PR, Cannovum AG Phone +49 30 3982 163 62, ir@cannovum.com Cannovum AG is the first German listed medical cannabis company. The shares are traded on the Düsseldorf, Munich, Berlin, Hamburg and gettex stock exchanges. Through its subsidiary Cannovum Health eG, Cannovum is a fully licensed pharmaceutical wholesaler, importer and manufacturer of high-quality medical cannabis products based in Berlin. The company focuses on the import of high-quality cannabinoid products, medical-scientific education and all-encompassing distribution for simplified and facilitated access to cannabis-based therapies.

For more information, visit www.cannovum.com

-----------------------------------------------------------------------------------------------------------------------

2021-09-08 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

----------------------------------------------------------------------------------------------------------------------- 


Language:     English 
Company:      Cannovum AG 
              Rheinsberger Str. 76/77 
              10115 Berlin 
              Germany 
Phone:        +49 (0)30 3982 16360 
E-mail:       ir@cannovum.com 
Internet:     www.cannovum.com 
ISIN:         DE000A2LQU21 
WKN:          A2LQU2 
Listed:       Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich 
EQS News ID:  1232051 
 
End of News   DGAP News Service 
=------------

1232051 2021-09-08

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1232051&application_name=news

(END) Dow Jones Newswires

September 08, 2021 07:44 ET (11:44 GMT)